S&P 500   3,397.89 (-0.09%)
DOW   27,554.04 (-0.47%)
QQQ   282.47 (+0.71%)
AAPL   116.22 (+1.02%)
MSFT   214.03 (+1.88%)
FB   283.84 (+2.43%)
GOOGL   1,593.36 (+0.57%)
AMZN   3,267.76 (+1.89%)
TSLA   422.32 (+0.49%)
NVDA   532.33 (+1.27%)
BABA   318.29 (+3.72%)
CGC   18.76 (+1.24%)
GE   7.16 (-2.98%)
MU   51.99 (-0.29%)
AMD   77.93 (-5.23%)
T   27.10 (-1.02%)
F   7.96 (-0.87%)
ACB   4.11 (-6.59%)
GILD   59.90 (-0.10%)
NFLX   486.98 (-0.26%)
NIO   27.81 (+6.92%)
BA   156.56 (-2.65%)
DIS   123.78 (-0.23%)
S&P 500   3,397.89 (-0.09%)
DOW   27,554.04 (-0.47%)
QQQ   282.47 (+0.71%)
AAPL   116.22 (+1.02%)
MSFT   214.03 (+1.88%)
FB   283.84 (+2.43%)
GOOGL   1,593.36 (+0.57%)
AMZN   3,267.76 (+1.89%)
TSLA   422.32 (+0.49%)
NVDA   532.33 (+1.27%)
BABA   318.29 (+3.72%)
CGC   18.76 (+1.24%)
GE   7.16 (-2.98%)
MU   51.99 (-0.29%)
AMD   77.93 (-5.23%)
T   27.10 (-1.02%)
F   7.96 (-0.87%)
ACB   4.11 (-6.59%)
GILD   59.90 (-0.10%)
NFLX   486.98 (-0.26%)
NIO   27.81 (+6.92%)
BA   156.56 (-2.65%)
DIS   123.78 (-0.23%)
S&P 500   3,397.89 (-0.09%)
DOW   27,554.04 (-0.47%)
QQQ   282.47 (+0.71%)
AAPL   116.22 (+1.02%)
MSFT   214.03 (+1.88%)
FB   283.84 (+2.43%)
GOOGL   1,593.36 (+0.57%)
AMZN   3,267.76 (+1.89%)
TSLA   422.32 (+0.49%)
NVDA   532.33 (+1.27%)
BABA   318.29 (+3.72%)
CGC   18.76 (+1.24%)
GE   7.16 (-2.98%)
MU   51.99 (-0.29%)
AMD   77.93 (-5.23%)
T   27.10 (-1.02%)
F   7.96 (-0.87%)
ACB   4.11 (-6.59%)
GILD   59.90 (-0.10%)
NFLX   486.98 (-0.26%)
NIO   27.81 (+6.92%)
BA   156.56 (-2.65%)
DIS   123.78 (-0.23%)
S&P 500   3,397.89 (-0.09%)
DOW   27,554.04 (-0.47%)
QQQ   282.47 (+0.71%)
AAPL   116.22 (+1.02%)
MSFT   214.03 (+1.88%)
FB   283.84 (+2.43%)
GOOGL   1,593.36 (+0.57%)
AMZN   3,267.76 (+1.89%)
TSLA   422.32 (+0.49%)
NVDA   532.33 (+1.27%)
BABA   318.29 (+3.72%)
CGC   18.76 (+1.24%)
GE   7.16 (-2.98%)
MU   51.99 (-0.29%)
AMD   77.93 (-5.23%)
T   27.10 (-1.02%)
F   7.96 (-0.87%)
ACB   4.11 (-6.59%)
GILD   59.90 (-0.10%)
NFLX   486.98 (-0.26%)
NIO   27.81 (+6.92%)
BA   156.56 (-2.65%)
DIS   123.78 (-0.23%)
Log in
NASDAQ:CALT

Calliditas Therapeutics AB (publ) News Headlines

$25.68
+0.41 (+1.62 %)
(As of 10/27/2020 01:06 PM ET)
Add
Compare
Today's Range
$24.93
Now: $25.68
$26.00
50-Day Range
$22.47
MA: $25.10
$29.57
52-Week Range
$19.00
Now: $25.68
$32.07
Volume2,297 shs
Average Volume89,908 shs
Market Capitalization$615.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Calliditas Therapeutics AB (publ) (NASDAQ CALT) News Headlines Today

Source:
DateHeadline
Reviewing Calliditas Therapeutics AB (publ) (CALT) and Its RivalsReviewing Calliditas Therapeutics AB (publ) (CALT) and Its Rivals
americanbankingnews.com - October 27 at 2:24 PM
Comparing Legend Biotech (CALT) and Its CompetitorsComparing Legend Biotech (CALT) and Its Competitors
americanbankingnews.com - October 17 at 12:43 PM
Legend Biotech Corporation (NASDAQ:CALT) Given Consensus Recommendation of "Buy" by BrokeragesLegend Biotech Corporation (NASDAQ:CALT) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - October 14 at 6:52 AM
Legend Biotech Corporation (NASDAQ:CALT) Receives Consensus Rating of "Buy" from AnalystsLegend Biotech Corporation (NASDAQ:CALT) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - October 14 at 6:52 AM
Head to Head Comparison: Legend Biotech (CALT) vs. Its CompetitorsHead to Head Comparison: Legend Biotech (CALT) vs. Its Competitors
americanbankingnews.com - October 12 at 9:24 AM
Legend Biotech (NASDAQ:CALT) Reaches New 52-Week High at $28.63Legend Biotech (NASDAQ:CALT) Reaches New 52-Week High at $28.63
americanbankingnews.com - October 9 at 6:54 PM
Legend Biotech (NASDAQ:CALT) Shares Gap Up to $25.09Legend Biotech (NASDAQ:CALT) Shares Gap Up to $25.09
americanbankingnews.com - October 8 at 12:15 PM
Head-To-Head Comparison: Legend Biotech (CALT) vs. Its CompetitorsHead-To-Head Comparison: Legend Biotech (CALT) vs. Its Competitors
americanbankingnews.com - October 5 at 9:26 AM
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.